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Open Access

Rationale and design of the Novel Uses of
adaptive Designs to Guide provider
Engagement in Electronic Health Records
(NUDGE-EHR) pragmatic adaptive
randomized trial: a trial protocol
Julie C. Lauffenburger1,2* , Thomas Isaac3, Lorenzo Trippa4, Punam Keller5, Ted Robertson6, Robert J. Glynn1,
Thomas D. Sequist7, Dae H. Kim1,8, Constance P. Fontanet1,2, Edward W. B. Castonguay3, Nancy Haff1,2,
Renee A. Barlev1,2, Mufaddal Mahesri1, Chandrashekar Gopalakrishnan1 and Niteesh K. Choudhry1,2

Abstract
Background: The prescribing of high-risk medications to older adults remains extremely common and results in
potentially avoidable health consequences. Efforts to reduce prescribing have had limited success, in part because
they have been sub-optimally timed, poorly designed, or not provided actionable information. Electronic health
record (EHR)-based tools are commonly used but have had limited application in facilitating deprescribing in older
adults. The objective is to determine whether designing EHR tools using behavioral science principles reduces
inappropriate prescribing and clinical outcomes in older adults.
(Continued on next page)
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Methods: The Novel Uses of Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR)
project uses a two-stage, 16-arm adaptive randomized pragmatic trial with a “pick-the-winner” design to identify
the most effective of many potential EHR tools among primary care providers and their patients ≥ 65 years
chronically using benzodiazepines, sedative hypnotic (“Z-drugs”), or anticholinergics in a large integrated delivery
system. In stage 1, we randomized providers and their patients to usual care (n = 81 providers) or one of 15 EHR
tools (n = 8 providers per arm) designed using behavioral principles including salience, choice architecture, or
defaulting. After 6 months of follow-up, we will rank order the arms based upon their impact on the trial’s primary
outcome (for both stages): reduction in inappropriate prescribing (via discontinuation or tapering). In stage 2, we
will randomize (a) stage 1 usual care providers in a 1:1 ratio to one of the up to 5 most promising stage 1
interventions or continue usual care and (b) stage 1 providers in the unselected arms in a 1:1 ratio to one of the 5
most promising interventions or usual care. Secondary and tertiary outcomes include quantities of medication
prescribed and utilized and clinically significant adverse outcomes.
Discussion: Stage 1 launched in October 2020. We plan to complete stage 2 follow-up in December 2021. These
results will advance understanding about how behavioral science can optimize EHR decision support to improve
prescribing and health outcomes. Adaptive trials have rarely been used in implementation science, so these
findings also provide insight into how trials in this field could be more efficiently conducted.
Trial registration: Clinicaltrials.gov (NCT04284553, registered: February 26, 2020)
Keywords: Deprescribing, Older adults, Decision support, Pragmatic trial, Prescribing, Adaptive trial

Contributions to the literature
 Novel Uses of adaptive Designs to Guide provider
Engagement in Electronic Health Records (NUDGE-EHR) is a
16-arm adaptive randomized pragmatic trial to identify the
most effective of numerous electronic health record tools for
prescribing.

 Adaptive randomized trials, like the NUDGE-EHR trial, have
rarely been used in implementation science, largely due to a
limited understanding of practicalities conducting these
trials.

 Regardless of the outcomes of NUDGE-EHR itself, our approach offers important lessons for the conduct of trials in
implementation science, especially because methods to
identify how to best deliver evidence-based interventions
and more efficiently generate evidence are central to implementation science.

Background
Prescribing of potentially unsafe medications for older
adults remains extremely common [1–3]. More than
20% of older adults are chronically using at least one of
these medications [3–5]. Chronic use can result in adverse health consequences such as an increased risk of
hospitalizations, falls, and fractures [3, 6]. For instance,
benzodiazepines and sedative hypnotics are thought to
increase the 1-year risk of falling by 30% in older adults,
even among patients who have been using them [7, 8].
Despite strong clinical guidelines recommending

reductions in their use, a gap persists in how to achieve
deprescribing of high-risk medications in clinical
practice.
Several prior studies have evaluated strategies to deimplement the prescribing of high-risk medications to
older adults [4, 9–11]. Specific approaches have included
in-person patient education, pharmacist medication or
drug utilization reviews, clinician-facing education, or
referral to specialist care [11–13]. The vast majority of
these have been complex and multi-faceted, and the timing of intervention provision has also varied; some were
delivered at specific points in care which may be too
late, such as hospital or nursing home admission [14].
Collectively, these interventions have been only modestly
effective, perhaps in part due to issues of design or implementation, and substantial resources would be required to sustain their use.
Computerized clinical decision support tools in electronic health record (EHR) systems are a widely scalable
strategy to influence physician behavior and have demonstrated effectiveness in implementation science interventions to increase the uptake of preventive health
screenings, test ordering, and prescribing guidelineindicated medications [9, 15, 16]. Several prior studies
have evaluated the use of decision support to facilitate
the deprescribing of high-risk medications to older
adults and have found inconsistent results [17–21]. The
lack of effectiveness of these EHR interventions may
have resulted from aspects of their designs, such as their
not presenting clinically actionable information to overcome true barriers to de-prescribing like clinical inertia,
patient pressure, or limited access to alternative
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treatments, or the decision support being insufficiently
focused on workflow and cognitive heuristics, such as
providing large blocks of text to communicate risks [22–
24]. Their usability and likelihood of producing success
moving forward could also be hampered further by barriers recognized by implementation frameworks, like the
representativeness of participating providers and the
timing and cost of the interventions [25, 26].
Accordingly, the effectiveness of EHR decision support
tools for reducing the prescribing of high-risk
medications may be improved by incorporating design
principles of behavioral sciences, such as framing, precommitment/consistency, or boostering, which have
demonstrated impact on individual behavior in other
contexts [21, 27–33]. For example, providing information in terms of risks rather than benefits can make patients more willing to fill a prescribed medication [27,
34]. Similarly, using “defaults” within EHRs can increase
generic medication prescribing and ordering of recommended laboratory tests [32].
To fill this knowledge gap, we initiated Novel Uses of
adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) trial. Because
there are numerous ways in which EHR tools that incorporate behavioral science principles could be designed and because a direct comparison of approaches is
typically difficult to accomplish with parallel-group trials
[35, 36], thus, NUDGE-EHR uses an adaptive design, a
methodology that has rarely been used in implementation research [36]. Using this design will help identify
the best way to deliver deprescribing tools within an
EHR and will provide guidance on which specific components of these tools are most effective at changing
prescribing, which will inform implementation in other
settings. Regardless of study findings, NUDGE-EHR
could be used as a blueprint about how to consider and
overcome the practicalities of conducting adaptive trials
in implementation science.

Methods/design
Overall study design

NUDGE-EHR is a two-stage adaptive randomized pragmatic trial with a “pick the winner” design that seeks to
identify the optimal EHR tool for reducing the use of
benzodiazepines, sedative hypnotics (“Z-drugs”), and anticholinergics among older adults (Fig. 1). In stage 1, primary care providers (PCPs) at a large integrated delivery
network have been randomized to one of 15 active intervention arms or usual care. For stage 2, we will
randomize (a) stage 1 usual care providers to one of up
to the top 5 promising stage 1 treatment arms or to continue usual care and (b) stage 1 providers in the unselected arms (e.g., ranked lower than 5) will be randomly
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assigned to one of up to the top 5 promising arms or
usual care.
The study is funded by the NIH National Institute on
Aging. The trial was approved by the Mass General
Brigham institutional review board who waived informed
consent for all subjects. The study is registered with
clinicaltrials.gov
(NCT04284553,
first
registered
February 26, 2020) and overseen by a Data and Safety
Monitoring Board. The authors are solely responsible for
the design and conduct of this study and drafting and
editing of the paper and its final contents.
The trial was designed using Pragmatic Explanatory
Continuum Indicator Summary (PRECIS-2) trial guidance and reported using SPIRIT reporting guidelines
(full protocol in Supplement 1).
Study setting and subjects

NUDGE-EHR is being conducted at Atrius Health, a delivery network in Massachusetts that uses the Epic® EHR
system, the platform used by > 35% of US ambulatory
practices and 60% of large hospitals [37]. Atrius employs
approximately 220 PCPs at 31 practices who care for approximately 745,000 patients. Eligible study participants
include these PCPs (including physicians and PCPdesignated nurse practitioners and physician assistants)
and their patients.
Providers are eligible if they prescribed a high-risk
medication to ≥ 1 older adult in the 180 days before
stage 1 assignment. Eligible high-risk medications include benzodiazepines, Z-drugs (e.g., zolpidem), and
anticholinergics and were chosen based on clinical
guidelines like Choosing Wisely and Beers Criteria that
recommend reductions in use and they continue to be
over-prescribed [38–40]. For stage 1, eligible patients of
these providers are those aged ≥ 65 years and who have
been prescribed ≥ 90 pills of benzodiazepine or Z-drug
in the last 180 days, which most guidelines consider
“chronic” use [40]. For stage 2, eligibility will be identical
to stage 1 except that patients (and their providers) will
also be included in secondary analyses if they had been
prescribed ≥ 90 pills of eligible anticholinergics in the
last 180 days. We chose to include just benzodiazepines
and Z-drugs in stage 1 as these medications have similar
prescribing patterns and likely have less variation with
improved statistical power. For stage 2, we also included
anticholinergics to ensure generalizability to other
classes.
Interventions

Our intervention design was based upon a thorough review of peer-reviewed literature and two focus groups
with PCPs intended to understand barriers to and facilitators of appropriate prescribing. Based on their effectiveness in other settings, applicability to older adults,
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Randomize primary care providers to active arm or usual1 care
Randomize providers equally
to one of 15 active arms

Arm 3:
Arm 1:
Arm 2:
Order
Order
Open
entry alert encounter entry alert
alert
+ followup
message

Interim Analysis

Arm 4:
Open
encounter
alert +
follow-up
message

Arm 8:
Arm 9:
Arm 10:
Arm 5:
Arm 6:
Arm 7:
Arm 11:
Order
Open
Order
Open
Simplified Simplified
Preentry
encounter order entry
open
entry alert encounter commitment
alert +
alert +
alert
encounter + sign off
alert +
alert + Order
pre-visit
pre-visit
alert
alert
sign-off
entry alert
message message
alert

Arm 12:
Precommitment
alert + Open
encounter
alert

Arm 13:
Order entry
alert with
different risk
presentation

Arm 14:
Arm 16:
Arm 15:
Open
Non-enhanced Usual care (no
encounter
standard alert
alert)
alert with
different risk
presentation

Evaluate outcomes after 6-month follow-up (timing dictated by the average number of observed data points)

Stage 2: Adaptive Trial

Randomize usual care providers from Arm 16 to one
of (up to) the 5 most successful arms identified in
Phase 1 or to Usual care (1:1:1:1:1:1)
Arm 1:
TBD

Final Analysis

Arm 2:
TBD

Arm 3:
TBD

Arm 4:
TBD

Arm 5:
TBD

Arm 16:
Usual
care (no
alert)

Evaluate outcomes across all arms after 8-month follow-up

Fig. 1 Overview of the adaptive trial stages

and ability to be adapted to EHRs [30, 41–43], we selected nine behavioral principles for testing: salience, default bias, social accountability, timing of tools (e.g., an
aspect of choice architecture), boostering, “cold-state”
priming, simplification, pre-commitment/consistency,
and framing (Table 1) [28, 33, 42, 44, 45]. Using these
principles, we co-designed and iteratively tested the EHR
tools with our multidisciplinary team in the healthcare
system.
Arms 1 through 14 of stage 1 involve EHR tools that
incorporate the selected behavioral science principles
(Fig. 2). The central component of each intervention is
an enhanced EHR alert (Best Practice Advisory [BPA] in
Epic®). This alert provides information about risks of
continued medication use and contains an embedded
hyperlink to tips to help providers discuss medication
discontinuation with their patients (Supplement 2, eFigure 1). When the alert triggers, it defaults to an order
set (a SmartSet in Epic®) that provides alternative treatments, templated patient instructions, and relevant
referrals, such as to behavioral health. For the benzodiazepines and Z-drug alerts, the order set also includes
tapering algorithms to limit risks of withdrawal symptoms. These algorithms are customized to the specific
drug, dose, and frequency that the patient is taking along
with pre-filled directions to pharmacies dispensing the
taper (Supplement 2, eFigure 2) and customizable and
printable instructions for patients about how to gradually taper off these drugs (Fig. 3). The order set also allows providers to order alternative medications, refer
patients to a behavioral health specialist, and share

instructions with patients about how to make lifestyle
modifications to improve symptoms.
Arms 1 and 2 are “base” interventions in which the
alert either fires when the provider orders a medication
(arm 1) or opens an encounter (arm 2) for eligible patients during in-person or telehealth visits, which require
addressing before completing the intended action (Supplement 2, eFigure 3). Additional principles are incorporated in arms 3–14. In arms 3 and 4, providers have the
option of receiving a follow-up “booster” message (Supplement 2, eFigure 4). Arms 5 and 6 incorporate “cold
state” priming, where providers receive a message in the
EHR inbox 2 days before a scheduled visit with an eligible patient. Arms 7 and 8 involve simplified language
(Supplement 2, eFigure 5), whereas arms 9 and 10 test
an additional alert that occurs at the time of approving a
medication when it is reordered or refilled by support
staff such as a medical assistant (Supplement 2, eFigure
6). Arms 11 and 12 incorporate pre-commitment, in
which providers are prompted to first have a discussion
with their patient about medication risks and then, at a
subsequent visit, are prompted to actively deprescribe
the relevant medication (Supplement 2, eFigure 7). Arms
13 and 14 test framing risks based on guidelines and evidence instead of just presenting the risks quantitatively
(Supplement 2, eFigure 8).
Conversely, arm 15 is a basic EHR alert meant to
mimic clinical decision support that is currently most
commonly given to providers, i.e., without behavioral
science (Supplement 2, eFigure 9). Physicians randomized to usual care (arm 16) receive no new EHR alert.
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Table 1 Behavioral principles tested in the electronic health record tools across study arms
Behavioral principle

Definition in context of medication
prescribing

Modification made to electronic health record tool to incorporate
the principle

Trial arm(s) with
this modification

Salience

Noticeability or prominence of drug risk
information

Presenting information about drug risks in ways that makes the
information as impactful as possible

1–14

Default bias

Pre-set course of action that leverages
providers’ tendency to do status quo

Defaulting the options to (1) discontinuing the medication and (2)
opening an order set that contains dose tapers, alternatives, and
customized patient instructions

1–14

Social accountability

Willingness to accept responsibility for
prescribing action

Requiring providers to select “I accept the drug’s risks” or write a free-text 1–14
response if they decide not to discontinue the medication or order a taper
or alternative

Timing of information
(an aspect of choice
architecture)

Organization of the context and timing in
which providers make choices to influence
decision-making

Modifying the timing of the tool to occur at different times in provider
workflow (i.e., when ordering a medication, opening an encounter record,
or approving a medication refilled by clinical staff)

-At ordering: 1, 3,
5, 7, 9, 11, 13, 15
-At encounter
opening: 2, 4, 6, 8,
10, 12, 14
-At refill approval:
9, 10

Boostering

Renewal of the effect of a prior intervention

Providing an option for reminder message 4 weeks after a patient visit

3, 4

“Cold-state” priming

Pre-exposure to information affects
subsequent prescribing

Triggering an informational message 2 days before a scheduled visit with
an eligible patient

5, 6

Simplification

Simplification of risk information may make it
more understandable

Simplifying the medication risks and recommended action language in
the tool

7, 8

Pre-commitment/
consistency

Support of future decision to deprescribe by
first asking providers to commit to an easier
action

Prompting providers to discuss medication risks on their first visit (using a
patient hand-out in the EHR) before prompting providers to stop medication or order a dose taper when the patients return for follow-up

11, 12

Framing

Framing of risks in terms of clinical guidelines Framing of risks in terms of clinical guidelines and published evidence

13, 14

Abbreviation: EHR Electronic health record

Fig. 2 Enhanced electronic health record tool modified with behavioral principles that triggers when ordering one of the high-risk medications. a
Salience: Presenting information about risks impactfully. b Defaults: Defaulting options to (1) discontinuing the order and (2) opening an order set
containing dose tapers, alternatives, and patient instructions. c Social accountability: Requiring providers to select either “I accept the drug’s risks”
or write a free-test response if they do not discontinue the medication or order a taper. d Choice architecture: Modifying timing of the tool to
occur at different times in provider workflow
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Fig. 3 Customized patient instructions for medication tapering algorithms. The instructions for the first prescription for a dose reduction of a
once-daily benzodiazepine medication is shown

Presently, a system-generated informational alert fires
for all providers upon ordering a benzodiazepine; this
will fire across all arms non-differentially.
If patients are eligible for multiple classes of interest (e.g., benzodiazepines and Z-drugs), the EHR
tools will appear simultaneously. To supplement the
two focus groups, we also incorporated feedback
from the Internal Medicine Design team and clinical
pharmacists at Atrius. Finally, to fully ensure usercentered design, we conducted pilot testing with several providers not in the trial to assess usability,
feasibility, and appropriate firing of the tools following Agency for Healthcare Research and Quality
principles [46].

Stage 1
Randomization

In stage 1, we stratified the 201 eligible PCPs into 4
blocks (with 50 PCPs in 3 of the blocks and 51 PCPs in
the fourth) based on clinical practice size (i.e., number
of providers) and baseline rates of high-risk prescribing
(i.e., number of eligible patients). Within these blocks,
30 PCPs were randomly allocated using a random number generator to one of 15 active arms, and 20 PCPs
were allocated to usual care (in the 4th block, the extra
PCP was assigned to usual care). In this way, 120 PCPs
were assigned to an active intervention (n = 8 per intervention), and 81 PCPs were assigned to usual care. Providers were randomized using data from March 1 to
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August 31, 2020, and randomization was performed in
September 2020; stage 1 began in October 2020.
Outcomes

The trial outcomes are shown in Table 2 and will be
assessed using routinely collected structured EHR data
and/or administrative claims data on the patient level.
The primary outcome is a “reduction” in inappropriate
prescribing defined as either discontinuation of one of
the medication classes of interest or ordering of a medication taper. If either action is taken by the provider for
a specific patient in the 6-month follow-up, we will classify the patient as having had a reduction in inappropriate prescribing, even if there is an unexpected later
escalation. If a patient is eligible for > 1 therapeutic class
(e.g., a benzodiazepine and a Z-drug), we will consider a
patient as having met the primary outcome if there was
a reduction in any of their eligible medications. This primary outcome was chosen because it can be rapidly
measured to facilitate the adaptive trial. In secondary
analyses, we will analyze outcomes stratified by the patient’s number of eligible therapeutic classes (i.e., one,
two, or three).
Analysis plan

Six months after stage 1 launch, we will use multivariable regression to determine which of the behavioral
components in the EHR tools (e.g., boostering effects) is
associated with a reduction in inappropriate prescribing
(primary outcome) among eligible patients who presented to care. The behavioral components are shown as
factors for the models in Supplement 2, eTable 1. In specific, we will adjust for physician-level clustering and
multiple patient observations per physician using a generalized linear mixed model for binary outcomes. Based
upon this analysis, the 15 active arms will be ranked
based on their observed effect estimates compared with
usual care. Sample size estimates are described in stage
2. We will only present the study results at the end of
stage 2.
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Stage 2
Randomization

After the stage 1 analysis, we will randomize the 201
stage 1 providers as follows: (a) stage 1 usual care providers will be randomized to one of up to the top 5 most
promising treatment arms or to continue to receive
usual care (1:1:1:1:1:1) (Fig. 1), (b) stage 1 providers who
were previously in unselected treatment arms (e.g.,
ranked lower than 5) will be randomized to one of up to
the top 5 most promising arms or to usual care (1:1:1:1:
1:1), and (c) stage 1 providers who were previously in
the most promising arms will be randomly assigned to
continue to receive their original treatment assignments
or to usual care to test holdover/persistency effects (1:1).
If only 1 to 5 arms are ranked, we will choose those for
testing in stage 2 and randomize PCPs in equal proportions. If none of the arms are promising versus usual
care, we will combine intervention components within
the arms to enhance effectiveness.
In stage 2, as secondary analyses, we will also include
and randomize any additional providers who prescribed
≥ 1 eligible anticholinergic of ≥ 90 days to an older adult
in the prior 180 days and include these in the analysis.
Based on preliminary data, we expect an additional 10–
15 providers. We will also stratify based on clinic size
and baseline rates of prescribing in stage 2. Follow-up
will last approximately 8 months but will be based on
the average number of observations.

Outcomes

As in stage 1, the primary outcome will be a reduction
in inappropriate prescribing defined by discontinuation
of high-risk medications or ordering a gradual dose
taper. The measurement approach will be the same as
for stage 1. In secondary analyses, we will include anticholinergics; the primary outcome for this definition will
be a reduction in inappropriate prescribing defined by
discontinuation of high-risk medications (benzodiazepines, Z-drugs, or anticholinergics) or ordering a gradual
dose taper (benzodiazepines or Z-drugs).

Table 2 Trial outcomes
Type

Outcome

Data source

Definition

When outcome is
analyzed

Primary

Reduction in
inappropriate prescribing

EHR

Composite of (1) discontinuation of high-risk medications or (2) ordering a gradual dose taper

End of stages 1
and 2

EHR

Number of milligram equivalents of high-risk medications prescribed to
patients

End of stage 2

Quantity of medication
dispensed

Administrative
claims

Number of milligram equivalents of high-risk medications filled by
patients

End of stage 2

Adverse events

Administrative
claims

Occurrence of clinically significant adverse drug events, such as allcause hospitalizations, falls, and fractures

End of stage 2

Secondary Quantity of prescribing
Tertiary

Lauffenburger et al. Implementation Science

(2021) 16:9

At the end of stage 2, we will also measure other prescribing and clinical outcomes from the EHR including
the cumulative number of milligram equivalents of highrisk medications prescribed to patients (secondary outcome). Because claims data are available for a subset of
patients whose insurance is in risk-bearing contracts
with Atrius, we will also measure tertiary outcomes including the quantity of high-risk medications dispensed
in follow-up, measured in pharmacy claims, and the occurrence of clinically significant adverse drug events,
specifically diagnoses of sedation, cognitive impairment,
and falls or fractures, and all-cause hospitalizations,
measured in medical claims data.
We will also measure implementation outcomes informed by the RE-AIM and CFIR implementation
frameworks to provide insight into its implementation
and scalability to other healthcare settings [25, 47].
These outcomes will include characteristics of providers
evaluated in the trial compared with other Atrius providers, percentage and frequency of decision support firing as intended, frequency of using the SmartSet order
set, and feedback from clinics and providers about the
intervention about acceptability and sustainability after
completion of the trial.

Analytic plan

We will conduct analyses of the primary outcome using
generalized linear mixed model for binary outcomes to
determine whether any of the intervention arms are
more effective versus usual care. For secondary and tertiary outcomes, we will also use generalized linear mixed
models. Primary analyses will be unadjusted; however, if
there are strong patient-level predictors not balanced by
stratified randomization, we will adjust for these. We
will not include multiplicity adjustments in our statistical plan.

Sample size

Our null hypothesis is that rates of provider prescribing
(defined as a reduction in prescribing of high-risk medication) in any of the active intervention arms will be no
different than usual care. We determined our sample
size to have 80% power assuming that the baseline rate
of the composite outcome among usual care physicians
is 5% (i.e., that 5% of patients would have a medication
discontinued or a taper ordered in follow-up independent of the intervention) and that the effective interventions will increase the relative rate of deprescribing for
patients by 10% (i.e., an odds ratio of 1.10) with type I
error = 0.05 and correlation = 0.3 [11, 18, 48]. We assumed an average cluster size of 20 patients per provider
based on baseline data.
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Limitations

There are several potential limitations. These trials are
being conducted in one health system. The results may
also not be applicable to initial prescribing of these medications or deprescribing of other high-risk medications.
Patients with generalized anxiety or panic disorder or
followed by specialists may also be included, but this
would be non-differential. In addition, many of the tools
are alert-based; while we hypothesize that incorporating
behavioral science principles will reduce their likelihood
of being ignored by providers, it is possible that the tools
could increase alert fatigue [49]. However, the design
will more explicitly identify tools that may unnecessarily
increase alert fatigue and whether certain nudges work
for certain types of providers.

Discussion
Decision support in EHRs have shown promise in reducing high-risk prescribing for older adults, yet have not
quite met that potential. While EHR strategies are widely
used to support informational needs of providers, these
tools have demonstrated only modest effectiveness at
improving prescribing [49–53]. In a recent systematic review, 57% of studies found that decision support influenced provider behavior, yet effect sizes were small (i.e.,
mean change of < 5%), and many studies had a high-risk
of bias [54]. EHR tools may currently be ineffective in
part due to insufficient focus on factors behind clinical
inertia, prescribing behavior, or workflow. To our knowledge, only three trials have specifically studied decision
support for inappropriate prescribing in ambulatory
older adults, which found modest effectiveness [20, 21,
52, 55]. Other decision supports, such as prescribing defaults, have not to our knowledge been applied to inappropriate prescribing in older adults [32, 56].
Discontinuing a medication may also prevent additional
behavioral challenges, such as loss-aversion and endowment, compared with adding medication.
Once the trial is completed, these results will also need
to be considered in relation to other efforts to reduce inappropriate prescribing in older adults. Limited prior
evidence suggests that providing information alone via
decision support at the time of a patient encounter
could be insufficient at reducing prescribing on its own
[20, 21, 55]. Other interventions that are not exclusively
provider-facing, such as pharmacist interventions, including medication reviews, and in-person patient education, have also demonstrated some success in reducing
inappropriate prescribing, yet these can be more resource intensive and may require actions outside of typical clinical workflow [11, 21, 57]. As the capabilities of
EHRs increase, there still exists much opportunity to improve deprescribing efforts aimed at providers directly,
including leveraging different time points in workflow
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and presenting different types of tools to facilitate deprescribing [58, 59].
Over the past decades, behavioral sciences have provided great insight into how to change behaviors by better understanding individuals’ underlying motivations,
how they mentally “account” for various options, and
processes necessary for sustained changed [44, 45].
These observations and application of their principles
has effectively changed behavior in other settings and
are likely applicable to EHR systems to improve the uptake of evidence-based care, such as improving prescribing in older adults [60]. The effectiveness of tools could
be enhanced by leveraging principles of behavioral economics and related sciences, but they have had very limited application in EHRs and, more specifically, for
prescribing in older adults.
Because there are numerous ways these tools could be
designed and delivered using behavioral science, we are
using an adaptive trial. Adaptive trials are increasingly
emerging as options for increasing the efficiency and
scale of interventions tested in clinical medicine than
traditional parallel groups allow [61]. Accordingly, applying adaptive trials to delivering other healthcare interventions, such as in implementation research, would
allow the possibility of testing faster and with more efficiency [36]. Because implementation research seeks to
test how to promote uptake of evidence-based interventions and abandon strategies that are harmful, methods
to generate evidence faster are central to the field. In
specific, NUDGE-EHR will determine the components
of EHR tools that are most impactful at changing provider behavior, which is fundamentally an implementation question. By using a study design that allows for the
testing of different EHR implementation strategies, we
will provide generalizable evidence both to healthcare
practices about specific strategies that should be used in
EHRs as well as to implementation researchers about
the practicalities of how to test different delivery strategies simultaneously [62, 63].
Therefore, this overall approach, regardless of ultimate
outcomes of the study itself, could be replicated by
others to enhance the conduct and evaluation of pragmatic trials in implementation science. NUDGE-EHR
will advance our understanding about how behavioral
science can optimize clinical decision support to reduce
inappropriate prescribing and improve patient health
outcomes as well as how to use adaptive trial designs in
healthcare delivery and implementation science.
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8 Arm 13: Enhanced order entry alert with different risk framing. Supplement 2, eFigure 9 Arm 15: Non-enhanced order entry alert. Supplement 2, eTable 1 Behavioral principles in electronic health record tools
tested in regression model.
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